GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients

Conditions:   Melanoma;   Non-Small Cell Lung Cancer;   Squamous Cell Carcinoma of the Head and Neck
Interventions:   Drug: GR-MD-02;   Drug: Pembrolizumab
Sponsors:   Providence Health & Services;   Galectin Therapeutics Inc.
Recruiting - verified September 2017

http://ift.tt/2hjJ5qN